Multiple mechanisms including antiangiogenic activity and immunomodulation

The phrase "Multiple mechanisms including antiangiogenic activity and immunomodulation" refers to a therapeutic strategy rather than a single molecular entity. This combined approach is widely used in oncology, especially for solid tumors. Antiangiogenic agents (such as VEGF inhibitors like bevacizumab or tyrosine kinase inhibitors like axitinib and sunitinib) aim to disrupt tumor blood vessel formation, normalize abnormal tumor vasculature, and thereby reduce tumor growth and improve immune cell trafficking. Immunomodulatory drugs, particularly immune checkpoint inhibitors (such as pembrolizumab, atezolizumab, and others), release the brakes on the immune system to enhance anti-tumor responses. When these strategies are combined, there can be synergistic effects leading to improved outcomes in certain cancers, although efficacy can vary by tumor type and resistance remains an issue[4][2][6][7][8]. Key molecular targets involved in these mechanisms include VEGF, VEGFR-2, PD-1, PD-L1, and CTLA-4, among others. This mechanistic category does not map to a specific gene, protein, or molecular target[2][3][4][5][7].

Inhibition of VEGF/VEGFR signaling to suppress angiogenesis. Normalization of tumor vasculature to reduce hypoxia and improve immune cell infiltration. Immune checkpoint blockade (e.g., PD-1, PD-L1, CTLA-4) to relieve immunosuppression and enhance T cell–mediated anti-tumor responses. Remodeling of the tumor microenvironment to enhance antigen presentation and T cell function. Potential inhibition of additional pro-angiogenic pathways (e.g., ANGPT2/Tie2).